Most Read Articles
02 Dec 2017
The risk of congenital heart disease (CHD) Is significantly higher in foetuses conceived through in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), according to a recent study.
Pearl Toh, 5 days ago
A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.
01 Apr 2014
The basic life support (BLS) termination of resuscitation (TOR) rule recommends transport and continued resuscitation when cardiac arrest is witnessed by EMT-Ds, or there is a return of spontaneous circulation, or a shock is given.
03 Dec 2017
Treatment with the triple combination of amlodipine, losartan and rosuvastatin appears to be an effective therapeutic strategy for lowering blood pressure and low-density lipoprotein (LDL)-C levels in patients with comorbid hypertension and dyslipidaemia, according to a study.

High uric acid concentrations tied to hypertension

06 Sep 2017

Higher concentrations of serum and urinary uric acid may predict higher 24-hour mean arterial pressure (MAP) and hypertension, a recent study suggests.

Researchers performed cross-sectional analysis in 2,555 individuals (mean age 60.0 years; 52 percent men; 27 percent had type 2 diabetes) from The Maastricht Study. They also conducted multivariable regression analyses to assess the association of serum uric acid concentration and 24-hour urinary uric acid excretion, as proxy for uric acid production, with ambulatory 24-hour blood pressure, 24-hour MAP and hypertension.

Serum uric acid concentration (per SD of 81 μmol/l) correlated with higher 24-hour MAP (β, 0.63 mm Hg; 95 percent CI, 0.27 to 1.00) and positively correlated with hypertension (odds ratio [OR], 1.43; 1.27 to 1.61) after adjustment for traditional hypertension risk factors. Urinary uric acid excretion (per SD of 140 mg/day/1.73 m2) was associated with higher 24-hour MAP (β, 0.79 mm Hg; 0.46 to 1.12) and with hypertension (OR, 1.13; 1.02 to 1.25).

Moreover, serum and 24-hour urinary uric acid excretion were not significantly correlated with 24-hour pulse pressure. No interaction with sex or age existed for the said associations.

“These results suggest that serum and 24-hour urinary uric acid concentrations, the latter as proxy for uric acid production are, independent of each other, associated with BP and hypertension,” according to researchers.

“Accumulation of reactive oxygen species by increased uric acid production has been suggested as a possible underlying mechanism for the association between uric acid and high blood pressure,” they added.

In The Maastricht Study, researchers did not find evidence supporting the hypothesis that generalized microvascular dysfunction was the underlying mechanism for the association between uric acid and cardiovascular and renal diseases. [J Hypertens 2015;33:1651-7]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
02 Dec 2017
The risk of congenital heart disease (CHD) Is significantly higher in foetuses conceived through in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), according to a recent study.
Pearl Toh, 5 days ago
A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.
01 Apr 2014
The basic life support (BLS) termination of resuscitation (TOR) rule recommends transport and continued resuscitation when cardiac arrest is witnessed by EMT-Ds, or there is a return of spontaneous circulation, or a shock is given.
03 Dec 2017
Treatment with the triple combination of amlodipine, losartan and rosuvastatin appears to be an effective therapeutic strategy for lowering blood pressure and low-density lipoprotein (LDL)-C levels in patients with comorbid hypertension and dyslipidaemia, according to a study.